Everyone Is Watching the Wrong Lawsuit

Two skin substitute cases are moving through federal court in Texas. One lawsuit asks what CMS should pay going forward. Most of the wound care industry is watching that appeal over future reimbursement.

The case with greater financial consequence for many practices is the other one. It will determine whether money already paid can be taken back years later.

The Appeal Making the Headlines

The CAMPs Initiative challenged CMS's 2026 payment rule after the agency replaced average sales price reimbursement with a flat payment rate of roughly $127 per square centimeter. The coalition argues the rule is unlawful and should be overturned.

A federal district court dismissed the case earlier this year without deciding whether CMS acted correctly. The court concluded the challenge belonged first in Medicare's administrative review process because providers—not manufacturers or distributors—are the parties directly affected by reimbursement decisions.

CAMPs has appealed that ruling to the Fifth Circuit.

Even if the appeal succeeds, it does not immediately change reimbursement. At most, it returns the case to the trial court for a decision on the merits. If the rule is ultimately overturned, reimbursement may change going forward.

That is where the impact of this case ends.

The Case That Reaches Filed Claims

The second lawsuit begins where the first one stops.

A provider-led class action challenges the retroactive reclassification of previously paid skin substitute claims as experimental or investigational, along with the recoupments that followed. The question before the court is whether contractors can revisit claims that were paid, apply a different interpretation years later, and recover those payments.

Future reimbursement influences tomorrow's cases.

Retroactive recoupment reaches yesterday's.

CMS reduced payment for skin substitutes, but it did not eliminate coverage or issue a national non-coverage determination for the category. Advanced wound care remains a covered Medicare benefit when medical necessity requirements are met.

That distinction has already surfaced in administrative proceedings. In one Florida appeal involving a $3.2 million recoupment, an Administrative Law Judge rejected a contractor's attempt to characterize skin substitutes billed under Q codes as investigational. The provider prevailed, but only after absorbing the time, expense, and disruption required to defend the claims.

Winning the appeal did not erase the cost of getting there.

Why This Is the Risk Practices Should Be Watching

The industry's attention naturally follows reimbursement because reimbursement is visible.

Operational risk is less visible until the demand for repayment arrives.

CMS generally has four years to reopen and recoup claims under applicable authorities. For practices that billed skin substitutes throughout 2024 and 2025, the financial exposure extends well beyond today's payment rates.

For many practices, that is the larger financial question.

Where Bionavix Fits

Legal decisions will ultimately be resolved in court.

Operational risk is managed long before that.

Bionavix was built to help practices operate confidently within an increasingly complex reimbursement environment. Coverage interpretation, documentation strategy, product selection, payer navigation, and ongoing case support all influence whether a claim remains defensible years after treatment has been delivered.

The environment continues to evolve. Practices that understand both the reimbursement landscape and the audit landscape will be better positioned than those watching only one.

Meta description: Two federal lawsuits are shaping wound care in very different ways. Learn why Bionavix believes the greater financial risk may not be tomorrow's reimbursement—but yesterday's claims.

Keywords: skin substitute lawsuit, CMS recoupment wound care, CAMPs Initiative lawsuit, retroactive claims wound care, Bionavix wound care compliance

URL slug: /wound-care-skin-substitute-lawsuits